Research · Source update
Foundayo ACHIEVE-4 details cardiovascular safety results
Source context: Read the linked original research or registry entry for study status and limitations.
Lilly reported detailed ACHIEVE-4 results comparing orforglipron with insulin glargine in high-risk adults with type 2 diabetes. MyDosePro reviewed the originating organization's statement to identify the reported results and their limitations.
What prompted this update?
Lilly reported detailed ACHIEVE-4 results comparing orforglipron with insulin glargine in high-risk adults with type 2 diabetes. MyDosePro reviewed the originating organization's statement to identify the reported results and their limitations. The originating source is Lilly ACHIEVE-4 detailed results, dated 2026-09-30.
What did the source report?
The company said its prespecified cardiovascular comparison met noninferiority, along with changes in HbA1c and weight. ACHIEVE-4 studied oral orforglipron against insulin glargine in adults with type 2 diabetes at elevated cardiovascular risk.
How should the results be interpreted?
Noninferiority is not the same as a proven cardiovascular superiority claim; subgroup and secondary findings need context. A cardiovascular noninferiority result should not be translated into proof of a superiority benefit over standard cardiovascular care.
What remains uncertain?
These findings apply to the specific study, date, population, product and endpoint described in the primary source. The source may be a sponsor announcement before full peer-reviewed publication. Check the original document and current regulatory status before drawing conclusions about personal treatment. Where a study or subgroup result was first released by a manufacturer, it should not be treated as independent confirmation of every claim; compare the full protocol, population, endpoints and subsequent publications.
What does this mean for patients?
The comparator and study population are critical. Treatment decisions depend on approved labeling, individual medical circumstances, availability and actual insurance benefits. MyDosePro offers educational context, not individualized prescribing or coverage confirmation.
The bottom line
The comparator and study population are critical.
Written and published by MyDosePro as an educational explanation of publicly available evidence. The linked primary source is dated 2026-09-30. We identify trial registrations separately from published results and do not provide individual prescribing advice.
Primary sourceLilly ACHIEVE-4 detailed results ↗
Source event or update: 2026-09-30. Our interpretation is educational and does not replace medical or insurance advice.